Anzeige
Mehr »
Samstag, 04.10.2025 - Börsentäglich über 12.000 News
Innocan Pharma: Neues Medikament für den Massenmarkt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40DEH | ISIN: US09073Q3039 | Ticker-Symbol: 2F5
München
03.10.25 | 08:00
1,170 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR Chart 1 Jahr
5-Tage-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,1301,17013:03
0,0000,00003.10.

Aktuelle News zur SCINAI IMMUNOTHERAPEUTICS LTD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.09.Scinai Immunotherapeutics Ltd. - F-1, Registration statement for certain foreign private issuers2
22.09.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
SCINAI IMMUNOTHERAPEUTICS LTD Aktie jetzt für 0€ handeln
11.09.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
02.09.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer2
02.09.Scinai Immunotherapeutics Ltd.: Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet261JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
29.07.Scinai Immunotherapeutics stock soars on promising skin disease drug data8
12.06.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer3
05.06.Scinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.119The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing...
► Artikel lesen
02.06.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
30.05.Scinai Immunotherapeutics reports Q1 results1
30.05.Scinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn243JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on...
► Artikel lesen
07.05.Scinai Immunotherapeutics Ltd.: Scinai Announces Annual Financial Results for 202496JERUSALEM, May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
07.05.Scinai Immunotherapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers3
27.03.Scinai Immunotherapeutics Ltd.: Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions122Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus...
► Artikel lesen
22.11.24Scinai Immunotherapeutics Ltd.: Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million196JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1